Exelixis, Inc. (0IJO)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 64.69 |
|---|---|
| 52-week range | 39.70 – 66.00 |
| Return, 1 month / 3 months | +14.3% / +16.5% |
| Return, 1 year / 3 years | – / – |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 32.6% |
| Worst drawdown (1 year) | -12.5% |
| Average daily value traded | 0.11M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Exelixis is a biopharmaceutical company based in California that discovers and develops small-molecule medicines for cancer. Its main products are tablet treatments used in kidney cancer, liver cancer and a form of thyroid cancer, and it also runs clinical programmes testing combinations of its medicines with other therapies. Its customers are physicians, hospitals and cancer treatment centres, mainly in the United States, with additional sales in Europe and other markets through partners and its own commercial team.
The shares are listed on the London Exchange in UK under the code 0IJO, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Exelixis, Inc. (0IJO) trades on the London Exchange in UK. It last closed at USD 64.69 on 23 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 211 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 28.2% | ||
| From 52-week high | -1.1% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 16.5% | ||
| 6-month return | 41.0% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 74 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -12.5% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.11M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +14.3% |
| 3 months | +16.5% |
| 6 months | +41.0% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 58.05 / 50.47 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.99 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.